Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Post-translational modifications in bladder cancer: Expanding the tumor target repertoire.

Oo HZ, Seiler R, Black PC, Daugaard M.

Urol Oncol. 2018 Oct 17. pii: S1078-1439(18)30339-9. doi: 10.1016/j.urolonc.2018.09.001. [Epub ahead of print] Review.

PMID:
30342880
2.

Clinicopathological significance of RCAN2 production in gastric carcinoma.

Hattori Y, Sentani K, Shinmei S, Oo HZ, Hattori T, Imai T, Sekino Y, Sakamoto N, Oue N, Niitsu H, Hinoi T, Ohdan H, Yasui W.

Histopathology. 2018 Oct 11. doi: 10.1111/his.13764. [Epub ahead of print]

PMID:
30307052
3.

Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.

Todenhöfer T, Seiler R, Stewart C, Moskalev I, Gao J, Ladhar S, Kamjabi A, Al Nakouzi N, Hayashi T, Choi S, Wang Y, Frees S, Daugaard M, Oo HZ, Fisel P, Schwab M, Schaeffeler E, Douglas J, Hennenlotter J, Bedke J, Gibb EA, Fazli L, Stenzl A, Black PC.

Mol Cancer Ther. 2018 Dec;17(12):2746-2755. doi: 10.1158/1535-7163.MCT-18-0107. Epub 2018 Sep 27.

PMID:
30262589
4.

Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC.

Clin Cancer Res. 2018 Sep 17. doi: 10.1158/1078-0432.CCR-18-1106. [Epub ahead of print]

PMID:
30224344
5.

TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.

Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, Landi D, Rainusso N, Hicks J, Powell S, Baker ML, Wels WS, Koch J, Sorensen PH, Deneen B, Ellis MJ, Lewis MT, Hegde M, Fletcher BS, St Croix B, Ahmed N.

Cancer Res. 2018 Jan 15;78(2):489-500. doi: 10.1158/0008-5472.CAN-16-1911. Epub 2017 Nov 28. Erratum in: Cancer Res. 2018 Jun 15;78(12):3403.

PMID:
29183891
6.

Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.

Korpal M, Puyang X, Jeremy Wu Z, Seiler R, Furman C, Oo HZ, Seiler M, Irwin S, Subramanian V, Julie Joshi J, Wang CK, Rimkunas V, Tortora D, Yang H, Kumar N, Kuznetsov G, Matijevic M, Chow J, Kumar P, Zou J, Feala J, Corson L, Henry R, Selvaraj A, Davis A, Bloudoff K, Douglas J, Kiss B, Roberts M, Fazli L, Black PC, Fekkes P, Smith PG, Warmuth M, Yu L, Hao MH, Larsen N, Daugaard M, Zhu P.

Nat Commun. 2017 Jul 24;8(1):103. doi: 10.1038/s41467-017-00147-w.

7.

An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.

Seiler R, Oo HZ, Tortora D, Clausen TM, Wang CK, Kumar G, Pereira MA, Ørum-Madsen MS, Agerbæk MØ, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, Douglas J, Todenhöfer T, Esfandnia S, Battsogt D, Babcook JS, Al-Nakouzi N, Crabb SJ, Moskalev I, Kiss B, Davicioni E, Thalmann GN, Rennie PS, Black PC, Salanti A, Daugaard M.

Eur Urol. 2017 Jul;72(1):142-150. doi: 10.1016/j.eururo.2017.03.021. Epub 2017 Apr 10.

PMID:
28408175
8.

Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration.

Agerbaek MØ, Pereira MA, Clausen TM, Pehrson C, Oo HZ, Spliid C, Rich JR, Fung V, Nkrumah F, Neequaye J, Biggar RJ, Reynolds SJ, Tosato G, Pullarkat ST, Ayers LW, Theander TG, Daugaard M, Bhatia K, Nielsen MA, Mbulaiteye SM, Salanti A.

Int J Cancer. 2017 Apr 1;140(7):1597-1608. doi: 10.1002/ijc.30575. Epub 2017 Feb 6.

9.

Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.

Clausen TM, Pereira MA, Al Nakouzi N, Oo HZ, Agerbæk MØ, Lee S, Ørum-Madsen MS, Kristensen AR, El-Naggar A, Grandgenett PM, Grem JL, Hollingsworth MA, Holst PJ, Theander T, Sorensen PH, Daugaard M, Salanti A.

Mol Cancer Res. 2016 Dec;14(12):1288-1299. Epub 2016 Sep 21.

10.

Real-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting.

Clausen TM, Pereira MA, Oo HZ, Resende M, Gustavson T, Mao Y, Sugiura N, Liew J, Fazli L, Theander TG, Daugaard M, Salanti A.

Sens Biosensing Res. 2016 Jul;9:23-30.

11.

Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy.

Hayashi T, Gust KM, Wyatt AW, Goriki A, Jäger W, Awrey S, Li N, Oo HZ, Altamirano-Dimas M, Buttyan R, Fazli L, Matsubara A, Black PC.

Clin Cancer Res. 2016 Jun 15;22(12):2981-92. doi: 10.1158/1078-0432.CCR-15-2360. Epub 2016 Jan 14.

12.

Hepatoma-derived growth factor-related protein 2 promotes DNA repair by homologous recombination.

Baude A, Aaes TL, Zhai B, Al-Nakouzi N, Oo HZ, Daugaard M, Rohde M, Jäättelä M.

Nucleic Acids Res. 2016 Mar 18;44(5):2214-26. doi: 10.1093/nar/gkv1526. Epub 2015 Dec 31.

13.

Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.

Salanti A, Clausen TM, Agerbæk MØ, Al Nakouzi N, Dahlbäck M, Oo HZ, Lee S, Gustavsson T, Rich JR, Hedberg BJ, Mao Y, Barington L, Pereira MA, LoBello J, Endo M, Fazli L, Soden J, Wang CK, Sander AF, Dagil R, Thrane S, Holst PJ, Meng L, Favero F, Weiss GJ, Nielsen MA, Freeth J, Nielsen TO, Zaia J, Tran NL, Trent J, Babcook JS, Theander TG, Sorensen PH, Daugaard M.

Cancer Cell. 2015 Oct 12;28(4):500-514. doi: 10.1016/j.ccell.2015.09.003.

14.

Significance of miR-148a in Colorectal Neoplasia: Downregulation of miR-148a Contributes to the Carcinogenesis and Cell Invasion of Colorectal Cancer.

Hibino Y, Sakamoto N, Naito Y, Goto K, Oo HZ, Sentani K, Hinoi T, Ohdan H, Oue N, Yasui W.

Pathobiology. 2015;82(5):233-41. doi: 10.1159/000438826. Epub 2015 Sep 22.

15.

Fukutin, identified by the Escherichia coli ampicillin secretion trap (CAST) method, participates in tumor progression in gastric cancer.

Oo HZ, Sentani K, Mukai S, Hattori T, Shinmei S, Goto K, Sakamoto N, Naito Y, Anami K, Trang PT, Yanagihara K, Oue N, Yasui W.

Gastric Cancer. 2016 Apr;19(2):443-52. doi: 10.1007/s10120-015-0511-2. Epub 2015 Jul 30.

PMID:
26223471
16.

Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer.

Hayashi T, Seiler R, Oo HZ, Jäger W, Moskalev I, Awrey S, Dejima T, Todenhöfer T, Li N, Fazli L, Matsubara A, Black PC.

J Urol. 2015 Oct;194(4):1120-31. doi: 10.1016/j.juro.2015.05.087. Epub 2015 Jun 3.

PMID:
26047983
17.

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS, Maude S, Teachey DT, Barrett DM, Orentas RJ, Daugaard M, Sorensen PH, Grupp SA, Fry TJ.

Blood. 2015 Jul 30;126(5):629-39. doi: 10.1182/blood-2014-11-612903. Epub 2015 Jun 3.

18.

TSPAN8, identified by Escherichia coli ampicillin secretion trap, is associated with cell growth and invasion in gastric cancer.

Anami K, Oue N, Noguchi T, Sakamoto N, Sentani K, Hayashi T, Naito Y, Oo HZ, Yasui W.

Gastric Cancer. 2016 Apr;19(2):370-80. doi: 10.1007/s10120-015-0478-z. Epub 2015 Feb 25.

PMID:
25711980
19.

MicroRNA-145 is a potential prognostic factor of scirrhous type gastric cancer.

Naito Y, Yasuno K, Tagawa H, Sakamoto N, Oue N, Yashiro M, Sentani K, Goto K, Shinmei S, Oo HZ, Yanagihara K, Hirakawa K, Yasui W.

Oncol Rep. 2014 Oct;32(4):1720-6. doi: 10.3892/or.2014.3333. Epub 2014 Jul 16.

PMID:
25051317
20.

Overexpression of ZDHHC14 promotes migration and invasion of scirrhous type gastric cancer.

Oo HZ, Sentani K, Sakamoto N, Anami K, Naito Y, Uraoka N, Oshima T, Yanagihara K, Oue N, Yasui W.

Oncol Rep. 2014 Jul;32(1):403-10. doi: 10.3892/or.2014.3166. Epub 2014 May 6.

PMID:
24807047
21.

Identification of novel transmembrane proteins in scirrhous-type gastric cancer by the Escherichia coli ampicillin secretion trap (CAST) method: TM9SF3 participates in tumor invasion and serves as a prognostic factor.

Oo HZ, Sentani K, Sakamoto N, Anami K, Naito Y, Oshima T, Yanagihara K, Oue N, Yasui W.

Pathobiology. 2014;81(3):138-48. doi: 10.1159/000357821. Epub 2014 Mar 8.

22.

NRD1, which encodes nardilysin protein, promotes esophageal cancer cell invasion through induction of MMP2 and MMP3 expression.

Uraoka N, Oue N, Sakamoto N, Sentani K, Oo HZ, Naito Y, Noguchi T, Yasui W.

Cancer Sci. 2014 Jan;105(1):134-40. doi: 10.1111/cas.12316. Epub 2013 Nov 29.

23.

Liver-intestine cadherin induction by epidermal growth factor receptor is associated with intestinal differentiation of gastric cancer.

Sakamoto N, Oue N, Sentani K, Anami K, Uraoka N, Naito Y, Oo HZ, Hinoi T, Ohdan H, Yanagihara K, Aoyagi K, Sasaki H, Yasui W.

Cancer Sci. 2012 Sep;103(9):1744-50. doi: 10.1111/j.1349-7006.2012.02353.x. Epub 2012 Jul 16.

24.

Upregulation of HOXA10 in gastric cancer with the intestinal mucin phenotype: reduction during tumor progression and favorable prognosis.

Sentani K, Oue N, Naito Y, Sakamoto N, Anami K, Oo HZ, Uraoka N, Aoyagi K, Sasaki H, Yasui W.

Carcinogenesis. 2012 May;33(5):1081-8. doi: 10.1093/carcin/bgs121. Epub 2012 Mar 12.

PMID:
22411957
25.

Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer.

Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, Sentani K, Oue N, Yasui W.

Pathol Int. 2012 Feb;62(2):112-9. doi: 10.1111/j.1440-1827.2011.02760.x. Epub 2011 Nov 30.

PMID:
22243781
26.

Identification of transmembrane protein in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of CDON is involved in tumor cell growth and invasion.

Hayashi T, Oue N, Sakamoto N, Anami K, Oo HZ, Sentani K, Ohara S, Teishima J, Matsubara A, Yasui W.

Pathobiology. 2011;78(5):277-84. doi: 10.1159/000329588. Epub 2011 Aug 17.

Supplemental Content

Support Center